Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Arteriovenous malformations; Meningioma; Necrosis; Neurilemmoma; Trigeminal neuralgia
- Focus Therapeutic Use
- Acronyms LIBERTI
- Sponsors Norton Healthcare Limited
- 09 Oct 2017 Planned number of patients changed from 15 to 10.
- 09 Oct 2017 Planned End Date changed from 1 Jun 2019 to 1 Nov 2019.
- 09 Oct 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.